Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors

被引:17
作者
Matsukuma, Karen [1 ]
Olson, Kristin A. [1 ]
Gui, Dorina [1 ]
Gandour-Edwards, Regina [1 ]
Li, Yueju [2 ]
Beckett, Laurel [2 ]
机构
[1] Univ Calif Davis, Dept Pathol & Lab Med, 4400 5 St, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA
关键词
PROLIFERATIVE INDEX; LABELING INDEX; REPRODUCIBILITY; QUANTIFICATION; CLASSIFICATION;
D O I
10.1038/modpathol.2016.225
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
A common problem in the assessment of Ki67 proliferative index in well-differentiated gastrointestinal neuroendocrine tumors is distinguishing tumor from non-tumor. This is because background stromal lymphocytes, entrapped non-neopiastic glands, and the delicate vascular network characteristic of neuroendocrine tumors frequently contain a subset of proliferating cells. Furthermore, in small biopsies, crush and cautery artifact can alter the morphologic appearance of tumor cells, making the Ki67 proliferative index more difficult to assess. To address these issues, we developed a synaptophysin-Ki67 double stain using a commercially available immunohistochemistry kit, allowing simultaneous visualization of tumor and proliferating nuclei. To test this method, three gastrointestinal pathologists individually graded 50 gastrointestinal neuroendocrine tumors first using synaptophysin-Ki67 double-stained slides and then, after a washout period, using Ki67-only stained slides (along with routine hematoxylin- and eosin-stained slides). Interobserver agreement on Ki67 proliferative index was moderate using the Ki67-only stained slides (intraclass correlation 0.51, 95% confidence interval: 0.35-0.66) and improved using the synaptophysin-Ki67 double stain (intraclass correlation 0.79, 95% confidence interval: 0.69-0.86). Similarly, interobserver agreement on tumor grade was fair with Ki67-only stained slides (kappa = 0.39, P<0.001) and improved with the double stain (kappa=0.58, P<0.001). Analysis of individual pathologists' scores revealed that fewer total number of tumor cells counted correlated with higher grade designation and appeared to contribute to grade discordance. In tumors cited as particularly challenging to assess by the pathologists, three of four tumors were grade discordant with the Ki67-only stain, whereas all four tumors were grade concordant with the synaptophysin-Ki67 stain. The synaptophysin-Ki67 double stain is the first technique to address specifically the histomorphologic challenges of evaluating Ki67 proliferative index in well-differentiated gastrointestinal neuroendocrine tumors. Although further validation is needed, this study provides evidence that the synaptophysin-Ki67 double stain can improve interobserver agreement.
引用
收藏
页码:620 / 629
页数:10
相关论文
共 24 条
[1]   Ki67 Labeling Index in Neuroendocrine Tumors of the Gastrointestinal and Pancreatobiliary Tract To Count or Not to Count Is Not the Question, But Rather How to Count [J].
Adsay, Volkan .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (12) :1743-1746
[2]  
[Anonymous], 2010, WHO CLASSIFICATION T
[3]  
[Anonymous], SAS ICC9 MACRO 2010
[4]  
[Anonymous], MAGR MACR V1 0
[5]  
[Anonymous], BR J CANC
[6]  
[Anonymous], NEUROENDOCRINOLOGY
[7]   Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors [J].
Blank, Annika ;
Wehweck, Laura ;
Marinoni, Ilaria ;
Boos, Laura Amanda ;
Bergmann, Frank ;
Schmitt, Anja Maria ;
Perren, Aurel .
VIRCHOWS ARCHIV, 2015, 467 (05) :543-550
[8]   Comparison of Methods for Proliferative Index Analysis for Grading Pancreatic Well-Differentiated Neuroendocrine Tumors [J].
Goodell, Pamela P. ;
Krasinskas, Alyssa M. ;
Davison, Jon M. ;
Hartman, Douglas J. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 137 (04) :576-582
[9]  
HANKINSON SE, 1995, CANCER EPIDEM BIOMAR, V4, P649
[10]   Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J].
Harvey, JM ;
Clark, GM ;
Osborne, CK ;
Allred, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1474-1481